MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: MMS_Medical_Surgical Training & Simulation
Osso VR
Industry: Silicon Valley, California
Guardant Health Inc. (NASDAQ:GH)*
Organization & Developments: Guardant Health
Parents
Guardant Health Inc. (NASDAQ:GH)*
Children
*Guardant Health was formed in 2013 with the audacious goal of conquering cancer with data and being a leader in the space of liquid biopsy testing
*GUARDANT360 CDx
*Its product suite utilizes a Cell-Free DNA "ctDNA," including Circulating-Tumor DNA "ctDNA" —the cancer genome found in the blood— to deliver oncology testing services to patients and physicians
*Revenue streams are diversified across three main buckets of cancer care (therapy selection, recurrence monitoring, and early detection)
*The company is focused on the development and commercialization of genetic profiling to enhance treatment outcomes of various cancers.
*The company's platform allows noninvasive access to molecular information of a tumor.
2019: Genetic Testing Companies Take DNA Tests To A Whole New Level
2019: Guardant Health Looks Forward To The Liquid Biopsy Opportunity In 2019_seekingalpha.com
2019: Guardant Health: Bright Future For Liquid Biopsy Leader, But Valuation Is Rich_seekingalpha.com
2019: Guardant Health: Profiting From Precision Medicine_seekingalpha.com
2019: Guardant Q2 sales soar on liquid biopsy adoption
2019: Market's leading comprehensive liquid biopsy (served over 60,000 oncologists and 50 biopharma companies with over 80,000 tests ordered).
2020: Guardant Health teams up with Janssen to develop liquid biopsy diagnostic
2020: Guardant Health: Strong Momentum And Enormous Opportunities
2021: Guardant’s liquid biopsy detects 96% of early-stage colorectal cancer cases with a single blood draw: study
2022: Guardant Health Unlikely To Regain Growth Premium Anytime Soon (Rating Downgrade)_ seekingalpha.com
2022: Guardant Health, Inc. 2022 Q3 - Results - Earnings Call Presentation _seekingalpha.com
2022: Guardant: A Temporary Exemption From The Gene Testing Market New Paradigm_ seekingalpha.com
2022: Guardant: Saving Lives One Blood Test At A Time_seekingalpha.com
2022: Guardant360 CDx is an FDA-approved comprehensive liquid biopsy for all advanced solid tumors.
2023: Guardant Health: Peeling Back Economic Layers, Compressed Market Values Appear Justified
2023: Winner: Guardant 360 CDx_The best medtech innovations of 2023
2024: Guardant Health, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
2024: Guardant: Double-Digit Sales Projections Come At A Cost
2025: Guardant Health at Barclays Conference: Strategic Expansion in Diagnostics
2025: Guardant Health rises after Medicare ADLT status for colorectal cancer test_MSN
2025: Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity
2025: Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
2025: Guardant's Blood Test Can Detect 8 Cancers With 98% Accuracy
2026: FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
2026: Guardant Health Summary: J.P. Morgan Healthcare Conference (January 2026)
2026: New cancer blood test gains FDA approval with 100x wider gene view
Guardant Health: Guardant360 CDx (also nominated in 2024
Jumps
*Key People: Guardant Health
Finance & Acquisitions: Guardant Health